Antibody Strategy Targets Epstein-Barr Virus to Shield Transplant Patients
TL;DR
Fred Hutch researchers produced fully human monoclonal antibodies against EBV by targeting its gp350 and gp42 proteins. In humanized mice, one antibody completely prevented EBV infection and another offered partial protection, outlining a pathway to prevent EBV reactivation and PTLD in transplant patients. The team aims to advance safety testing in healthy volunteers followed by trials in immunocompromised individuals, with IP protection filed for the antibodies.
- Breakthrough Discovery Targets Virus Infecting 95% of the World’s Population SciTechDaily
- Fred Hutch scientists reach crucial milestone in blocking Epstein Barr virus News-Medical
- Scientists Create Groundbreaking Antibody to Halt Epstein-Barr Virus Bioengineer.org
- First-of-its-kind antibody blocks Epstein Barr virus - carried by 95% of people AOL.com
- New Antibodies Could Finally Block One of the World’s Stealthiest Viruses ScienceBlog.com
Want the full story? Read the original reporting
Read on SciTechDaily